Trabodenoson

SKU: orb1695021

Description

Trabodenoson (INO-8875) is a selective adenosine A1 receptor agonist used in ophthalmic research. It has been investigated in preclinical and clinical studies for intraocular pressure reduction in primary open-angle glaucoma, exploring its mechanism in both in vitro and in vivo models.

Research Area

Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 871108-05-3
• MW: 380.36
• Purity: 99.94%
• Formula: C₁₅H₂₀N₆O₆
• SMILES: O[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@H]([C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12
• Target: Adenosine Receptor
• Solubility: DMSO:100 mg/mL (262.91 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (10.52 mM)

Bioactivity

• In Vivo:
  Trabodenoson (6.0%) demonstrates an average IOP drop of 2.45 ± 0.38 mm Hg in young mice over 7 days (downregulation). In induced eyes, topical trabodenoson significantly upregulates nestin expression in the ONH compared with vehicle-treated non-induced eyes. Trabodenoson-treated eyes show significantly reduced optic nerve (ON) edema compared with vehicle-treated eyes. Additionally, RGC counts are higher in Trabodenoson-treated eyes compared to vehicle, accounting for 74% versus 47% of the contralateral eye.
• In Vitro:
  Treatment with Trabodenoson significantly increases MMP-2 activity and MMP-14 abundance, while decreasing expression of fibronectin and collagen IV.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

INO-8875, INNO 8875, INNO8875, INNO-8875, A1, AdenosineReceptor, Adenosine Receptor, Trabodenoson, PJ 875, PJ875, PJ-875

Compound Identifiers

PubChem CID

11610599